Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Evidence for an association of HLA-DRB1*15 and DRB1*09 with leprosy and the impact of DRB1*09 on disease onset in a Chinese Han population

  • Furen Zhang1, 2Email author,
  • Hong Liu1,
  • Shumin Chen1,
  • Changyuan Wang1,
  • Chuanfu Zhu3,
  • Lin Zhang1,
  • Tongsheng Chu1,
  • Dianchang Liu1,
  • Xiaoxiao Yan1 and
  • Jianjun Liu1, 4
BMC Medical Genetics200910:133

https://doi.org/10.1186/1471-2350-10-133

Received: 16 February 2009

Accepted: 11 December 2009

Published: 11 December 2009

Abstract

Background

Human leukocyte antigens (HLAs) have been proposed to modulate the immune response to Mycobacterium leprae. The association of HLA-DRB1 with leprosy has been reported in several populations, but not in a Chinese population.

Methods

The polymerase chain reaction-sequence-specific oligonucleotide probe with Luminex100 (PCR-SSOP-Luminex) method was used to genotype HLA-DRB1 alleles in 305 leprosy patients and 527 healthy control individuals.

Results

The HLA-DRB1*15 allele was significantly more prevalent among leprosy patients than healthy controls, whereas the frequency of the HLA-DRB1*09 allele was lower among leprosy patients, especially those with early-onset disease.

Conclusion

HLA-DRB1 alleles are associated with leprosy susceptibility in a Chinese population. The HLA-DRB1*09 allele was found to be protective exclusively in a subset of early-onset leprosy patients.

Background

Leprosy is a chronic infectious disease that occurs in genetically predisposed individuals. It is caused by infection with the intracellular macrophage pathogen Mycobacterium leprae. Leprosy is characterized by a spectrum of disease symptoms that result from interactions between the host immune response and invading M. leprae. At the lepromatous extreme, patients exhibit multibacillary infection and an absence of antigen-specific cellular immunity. At the tuberculoid extreme, patients exhibit paucibacillary infection and a strong cellular immune response. Between these two extremes, borderline leprosy patients show intermediate phenotypes [1].

Leprosy was once prevalent worldwide. However, there has been a steady decline in the prevalence of leprosy since the introduction of multidrug therapy by the World Health Organization (WHO-MDT) in 1982 [2]. The detection rate of new cases, however, remains steady in some countries, including several regions of China [3, 4]. Since 2002, nearly 1,600 new cases have been detected annually in China [4].

Previous studies have suggested a strong influence of genetic factors in regulation of the anti-M. leprae immune response [5, 6]. Two recent genome-wide linkage analyses have identified chromosome 6p21 as a major leprosy-susceptibility locus [7, 8]. This region harbors the HLA gene cluster, which has been extensively studied for its role in leprosy pathogenesis [912]. In particular, HLA-DR alleles have been consistently found to be associated with leprosy [13]. Several studies reported an association of the HLA-DR2 alleles HLA-DRB1*15, *16 *04, *10 and *12 with susceptibility or resistance to leprosy in Brazilian, Vietnamese, South Indian, Indonesian, Thai and Argentine populations [1418]. In addition, HLA-DR3 alleles were also found to be associated with leprosy susceptibility in Surinamese and Mexican populations [19, 20]. These studies have not only shown the importance of the HLA-DR locus in leprosy susceptibility, but have also highlighted the fact that different HLA-DR alleles are associated with leprosy in different populations.

Although leprosy remains a major public health concern and one of the infectious diseases most capable of causing disability in China, the genetic susceptibility to leprosy in Chinese populations has received little study. The only such report was an investigation of the association of HLA-DRB1 with leprosy in Southern China; however, due to the small sample used, this study failed to detect this well-established association [21]. In the current study, we investigated the association of HLA-DRB1 with leprosy by genotyping DRB1 alleles in a large Chinese Han sample of 305 leprosy patients and 527 healthy control individuals. We further investigated the association of DRB1 alleles with clinical subtype and age-of-onset of the disease.

Methods

Patients and controls

The study included 305 unrelated individuals with a diagnosis of leprosy and 527 control samples. The diagnosis of leprosy was based on clinical assessment and detection of acid-fast bacilli in skin-slit smears and histopathological assessment of skin lesions. The patients were further classified as multibacillary (MB) or paucibacillary (PB) on the basis of clinical and histological criteria [1]. The MB patient subset (n = 179), which included patients with lepromatous leprosy (LL), borderline lepromatous leprosy (BL)and borderline (BB) leprosy, had a bacterial index (BI) > 0. The PB group (n = 126) had a BI = 0, and included patients with borderline tuberculoid leprosy (BT) and tuberculoid leprosy (TT). Control sample donors were recruited from the Shandong Blood Center. Some characteristics of the 305 cases and 527 controls are summarized in Table 1.
Table 1

Characteristics of the study population of 305 cases and 527 controls

 

Population

Sample size

(LL/BL/BB/BT/TT)

(MB/PB)

Male/Female

Mean age

Mean age onset

Case

Chinese Han

305

278/27

67.5

19.0

  

(158/15/6/6/120)

   
  

(179/126)

   

Control

Chinese Han

527

451/76

50.2

NA

NA: no onset age for controls

All subjects gave informed consent to participate in the study. The protocol was approved by the Ethical Committee of the Shandong Provincial Institute of Dermatovenereology.

DNA extraction and HLA-DRB1*typing

Genomic DNA was extracted from peripheral blood using a commercially available DNAzol extraction kit (E.Z.N.A Blood DNA KIT, Omega Bio-tek, Inc).

The procedure for HLA genotyping by the polymerase chain reaction-sequence-specific oligonucleotide probe with Luminex100 (PCR-SSOP-Luminex) method included PCR amplification, hybridization, a streptavidin-phycoerythrin (SA-PE) reaction, and analytical measurements [22]. Target DNA was amplified by PCR using 5' biotin-labeled primers that were highly specific to certain sequences of HLA-DRB1 genes. PCR was carried out in a 20 μL reaction containing Lifecodes mixture (6 μL), Taq polymerase (0.2 μL), nuclease-free water (11.8 μL) and genomic DNA (3 μL). After denaturization, amplified DNA was allowed to hybridize to complementary DNA probes coupled to microbeads. The oligobead-coupled, hybridized PCR product was labeled with streptavidin-phycoerythrin. The fluorescent intensity of phycoerythrin on each coded oligobead that had hybridized with the biotin-labeled PCR product was measured using a Luminex apparatus, and the HLA-DRB1* genotype was determined with the assistance of Genosearch typing software (Quick-Type for LifeMatch 2.0, Luminex Corporation). This HLA-typing analysis was done at the Shandong blood center.

Statistical analysis

Power calculations, carried out using PS software http://www.power-analysis.com/home.htm, showed that our sample size of 305 patients and 527 controls had greater than 95% power to detect an odds ratio (OR) of 2.0 at a significance level of 5% when the frequency of the allele of interest was greater than 0.10. Allele frequencies were calculated by direct counting. The differences in allele frequency between patients and controls and between early onset and late-onset patients were tested using logistic regression analyses with adjustments for age and gender. The significance of the allele frequency difference between the MB and PB cases was analyzed using Pearson Chi-square tests. The nominal P-values were corrected for multiple testing (Pc-value) using the Bonferroni correction (i.e., by multiplying the nominal P-values by the number of HLA alleles being tested). A Pc-value < 0.05 was accepted as statistically significant. The strength of associations was estimated by calculating ORs. Statistical analyses were carried out using SPSS software (version 11.0).

Results

Table 2 summarizes the allele frequencies of HLA-DRB1* alleles in the leprosy patient and control populations and the results of association analyses. Of the 13 HLA-DRB1 alleles determined by the PCR-SSOP-Luminex method, two alleles showed a significant difference in frequency (P < 0.05) between patients and controls. The frequency of the DRB1*15 allele among patients was 0.32 (195/610), which was significantly higher than the frequency of 0.18 (185/1054) observed in the healthy controls (P < 0.001). This difference remained significant after correcting for multiple testing (Pc < 0.001). In contrast, the frequency of the HLA-DRB1*09 allele was significantly lower in the patient population than among controls (P = 0.002, Pc = 0.026).
Table 2

Allele frequency distribution of HLA-DRB1* in patients versus controls, and MB versus PB forms of leprosy

 

Patients

Controls

  

MB

PB

 
 

(n= 305)

(n= 527)

  

(n = 179)

(n = 126)

 

Alleles

2 n

AF

2 n

AF

P -value

Pc -value

AF

AF

P -value

HLA-DRB1*01

19

0.03

23

0.02

0.246

 

0.02

0.04

0.136

HLA-DRB1*03

14

0.02

40

0.04

0.520

 

0.04

0.02

0.224

HLA-DRB1*04

44

0.07

98

0.09

0.387

 

0.09

0.09

0.471

HLA-DRB1*07

73

0.12

164

0.16

0.427

 

0.16

0.13

0.197

HLA-DRB1*08

30

0.05

53

0.05

0.965

 

0.05

0.04

0.497

HLA-DRB1*09

49

0.08

140

0.13

0.002

0.026

0.13

0.07

0.06

HLA-DRB1*10

5

0.01

13

0.01

0.564

 

0.01

0.00

0.571

HLA-DRB1*11

43

0.07

76

0.07

0.585

 

0.07

0.06

0.188

HLA-DRB1*12

61

0.10

114

0.11

0.879

 

0.11

0.12

0.705

HLA-DRB1*13

29

0.05

63

0.06

0.058

 

0.06

0.04

0.232

HLA-DRB1*14

31

0.05

52

0.05

0.522

 

0.05

0.06

0.183

HLA-DRB1*15

195

0.32

185

0.18

< 0.001

< 0.001

0.18

0.29

0.991

HLA-DRB1*16

17

0.03

33

0.03

0.844

 

0.03

0.03

0.838

n, number of individuals; AF, allelic frequency.

P-values are from allele-based tests.

We further investigated the association of HLA-DRB1* alleles with the clinical subtypes of leprosy. No significant differences in the allele frequencies were observed between the MB and PB forms of the disease (Table 2). We then investigated the association of HLA-DRB1* alleles with early-onset (age-at-onset ≤ 16 years; n = 141) and late-onset (age-at-onset > 16 years; n = 164) leprosy. Interestingly, whereas the DRB1*15 allele was significantly associated with both early- and late-onset leprosy, the DRB1*09 was only significantly associated with early-onset leprosy (Table 3).
Table 3

Allele frequency distribution of HLA-DRB1* in early versus late-onset leprosy groups

Alleles

Controls

Early onset

  

Late-onset

  
 

(n = 527)

(n = 141)

  

(n = 164)

  
 

AF

AF

P -value

Pc -value

AF

P -value

Pc -value

HLA-DRB1*01

0.02

0.03

0.924

 

0.04

0.162

 

HLA-DRB1*03

0.04

0.03

0.848

 

0.02

0.320

 

HLA-DRB1*04

0.09

0.09

0.685

 

0.06

0.406

 

HLA-DRB1*07

0.16

0.10

0.130

 

0.14

0.848

 

HLA-DRB1*08

0.05

0.05

0.926

 

0.05

0.723

 

HLA-DRB1*09

0.13

0.06

0.003

0.039

0.10

0.256

 

HLA-DRB1*10

0.01

0.003

0.168

 

0.01

0.285

 

HLA-DRB1*11

0.07

0.07

0.688

 

0.07

0.503

 

HLA-DRB1*12

0.11

0.11

0.480

 

0.09

0.324

 

HLA-DRB1*13

0.06

0.04

0.017

0.221

0.05

0.429

 

HLA-DRB1*14

0.05

0.05

0.607

 

0.05

0.988

 

HLA-DRB1*15

0.18

0.35

< 0.001

< 0.001

0.29

< 0.001

< 0.001

HLA-DRB1*16

0.03

0.03

0.758

 

0.02

0.495

 

n, number of individuals; AF, allelic frequency.

P-values are from allele-based tests.

All markers with allele frequency above 0.01 have been tested and were in HW equilibrium.

Discussion

Leprosy is a chronic infectious disease caused by M. leprae. The disease only occurs in a small percentage (1-3%) of infected individuals [23], an observation that supports the important role of host genetic factors in the development of leprosy. The reported male-to-female patient ratio is 2:1 [24], consistent with the known role of gender as an independent risk factor for leprosy susceptibility. In our study, more male cases were collected than female cases; thus, the observed association of the HLA-DRB1 allele with leprosy was based on a mostly male population.

Many studies have reported an association of HLA-DR2 with leprosy, a linkage that is consistent with the finding that HLA-DR antigens are associated with disease and the suggestion that a majority of restriction determinants for M. leprae reside on DR, and not DP or DQ molecules [25]. A functional study of Ag-specific T-cell responses within the context of HLA-DR has shown that HLA-DR-associated immunity may be crucial in the adaptive immune response to infection [26]. Thus, HLA-DR plays a major role in the presentation of M. leprae antigens to T cells in leprosy patients.

By analyzing a large number of Chinese leprosy patients, our study has provided the first evidence for an association of HLA-DRB1 with leprosy in a Chinese population and provided additional support for the important role of HLA in the pathogenesis of leprosy. HLA-DRB1*15 has been demonstrated to be a leprosy-susceptibility allele among Brazilian [14] and Indian [15] populations. In our study, we found that HLA-DRB1*15 was also associated with an increased risk of leprosy in a Chinese population, and exhibited an allele frequency (32%) similar to that observed in Indian populations (31%) but higher than that observed among Brazilians (15%). The HLA-DRB1*09 allele was found to be associated with protection against leprosy in our study; its frequency was significantly lower in leprosy patients than in controls, and the association remained significant after correcting for multiple testing (P = 0.002, Pc = 0.026). This allele also showed a protective effect against the disease in Southern India, but the allele frequency among Indian patients was 0.017 [15], much lower than that observed in the Chinese population studied here (0.08).

It has been reported that the HLA lymphotoxin-alpha (LTA)+80 locus within the 6p21 chromosomal region is a major risk factor for early-onset (i.e., < 16 years old) leprosy [27]. To investigate whether the effect of HLA-DRB1* on leprosy risk was age-onset dependent, we stratified leprosy patients into early-onset (≤ 16 years) and late-onset (> 16 years) groups in association analyses. Interestingly, we found that HLA-DRB1*09 was associated with protection effect against early-onset leprosy (P = 0.003), but not late-onset leprosy (P = 0.285). In contrast, the HLA-DRB1*15 allele showed no age-onset-dependent effects. To our knowledge, this is the first report that HLA-DRB1*09 has an impact on disease onset. Further studies will be needed to investigate the association of the LTA+80 locus with leprosy in Chinese populations and determine whether the association at the HLA-DRB1 locus is independent of the LTA+80 locus.

De Vries et al. have proposed a two-step model for the development of leprosy, proposing that successful infection of M. leprae is first established in genetically vulnerable individuals, and subsequent clinical manifestation of the disease is influenced by additional host and environmental factors [28]. In our study, the frequencies of HLA-DRB1 alleles were similar in the MB and PB patient groups. This is consistent with the two-step model, suggesting that the HLA-DRB1 locus may influence the overall susceptibility to leprosy per se. It has also been reported that certain HLA-DRB1 alleles are associated with MB or PB forms of leprosy [2931], suggesting that HLA-DRB1 may also be involved in the clinical manifestation of the disease.

Taken together, our association analysis of stratified patient groups indicates that the HLA-DRB1 locus is largely associated with leprosy per se, and only HLA-DRB1*09 shows an age-onset-dependent effect.

Conclusion

In summary, by analyzing a large sample of Chinese Han leprosy patients, our genetic association study of the HLA-DRB1 locus provides strong evidence for an association of HLA-DRB1*15, as a susceptibility allele, and DRB1*09, as a protective allele, with leprosy in a Chinese population. Furthermore, we demonstrate for the first time that HLA-DRB1*09 has an impact on the onset of disease, exerting a protective effect only against early-onset leprosy. These alleles could act alone or in combination with other genes to confer susceptibility or resistance to leprosy in Chinese Han populations.

Abbreviations

HLA: 

human leukocyte antigen

MB: 

multibacillary

PB: 

paucibacillary

PCR: 

polymerase chain reaction

SSOP: 

sequence-specific oligonucleotide probe.

Declarations

Acknowledgements

This research was supported by National Natural Science Foundation of China (No. 30771943/C030116).

Authors’ Affiliations

(1)
Shandong Provincial Institute of Dermatovenereology
(2)
Shandong clinical college for skin diseases, Anhui medical university
(3)
Shandong blood center
(4)
Genome Institute of Singapore, A*STAR

References

  1. Ridley DS, Jopling WH: Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis. 1966, 34: 255-273.PubMedGoogle Scholar
  2. Noordeen SK: Elimination of leprosy as a public health problem: progress and prospects. Bull World Health Organ. 1995, 73: 1-6.PubMedPubMed CentralGoogle Scholar
  3. Huan-Ying L, Shun-Peng R, Rong-De Y: Leprosy control in a prefecture of Yunnan Province in the Peoples' Republic of China, using intensive health education of the public and primary health care workers for the detection of cases, 1998-1999. Lepr Rev. 2002, 73: 84-87.PubMedGoogle Scholar
  4. Zhang L, Budiawan T, Matsuoka M: Diversity of potential short tandem repeats in Mycobacterium leprae and application for molecular typing. J Clin Microbiol. 2005, 43: 5221-5229. 10.1128/JCM.43.10.5221-5229.2005.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Feitosa MF, Borecki I, Krieger H, Beiguelman B, Rao DC: The genetic epidemiology of leprosy in a Brazilian population. Am J Hum Genet. 1995, 56 (5): 1179-1185.PubMedPubMed CentralGoogle Scholar
  6. Beiguelman B: Some remarks on the genetics of leprosy resistance. Acta Genet Med Gemellol. 1968, 17: 584-594.PubMedGoogle Scholar
  7. Miller EN, Jamieson SE, Joberty C, Fakiola M, Hudson D, Peacock CS, Cordell HJ, Shaw MA, Lins-Lainson Z, Shaw JJ, Ramos F, Silveira F, Blackwell JM: Genome-wide scans for leprosy and tuberculosis susceptibility genes in Brazilians. Genes Immun. 2004, 5 (1): 63-67. 10.1038/sj.gene.6364031.View ArticlePubMedGoogle Scholar
  8. Mira MT, Alcaïs A, Van Thuc N, Thai VH, Huong NT, Ba NN, Verner A, Hudson TJ, Abel L, Schurr E: Chromosome 6q25 is linked to susceptibility to leprosy in a Vietnamese population. Nat Genet. 2003, 33 (3): 412-415. 10.1038/ng1096.View ArticlePubMedGoogle Scholar
  9. Santos AR, Suffys PN, Vanderborght PR, Moraes MO, Vieira LM, Cabello PH, Bakker AM, Matos HJ, Huizinga TW, Ottenhoff TH, Sampaio EP, Sarno EN: Role of tumor necrosis factor-alpha and interleukin-10 promoter gene polymorphisms in leprosy. J Infect Dis. 2002, 186 (11): 1687-1691. 10.1086/345366.View ArticlePubMedGoogle Scholar
  10. Roy S, McGuire W, Mascie-Taylor CG, Saha B, Hazra SK, Hill AV, Kwiatkowski D: Tumor necrosis factor promoter polymorphism and susceptibility to lepromatous leprosy. J Infect Dis. 1997, 176 (2): 530-532. 10.1086/517282.View ArticlePubMedGoogle Scholar
  11. de Vries RR, van Eden W, Ottenhoff TH: HLA class-II immune response genes and products in leprosy. Prog Allergy. 1985, 36: 95-113.PubMedGoogle Scholar
  12. Ottenhoff TH, Neuteboom S, Elferink DG, de Vries RR: Molecular localization and polymorphism of HLA class II restriction determinants defined by Mycobacterium leprae-reactive helper T cell clones from leprosy patients. J Exp Med. 1986, 164 (6): 1923-1939. 10.1084/jem.164.6.1923.View ArticlePubMedGoogle Scholar
  13. Moraes MO, Cardoso CC, Vanderborght PR, Pacheco AG: Genetics of host response in leprosy. Lepr Rev. 2006, 77 (3): 189-202.PubMedGoogle Scholar
  14. Vanderborght PR, Pacheco AG, Moraes ME, Antoni G, Romero M, Verville A, Thai VH, Huong NT, Ba NN, Schurr E, Sarno EN, Moraes MO: HLA-DRB1*04 and DRB1*10 are associated with resistance and susceptibility, respectively, in Brazilian and Vietnamese leprosy patients. Genes Immun. 2007, 8 (4): 320-324. 10.1038/sj.gene.6364390.View ArticlePubMedGoogle Scholar
  15. Tosh K, Ravikumar M, Bell JT, Meisner S, Hill AV, Pitchappan R: Variation in MICA and MICB genes and enhanced susceptibility to paucibacillary leprosy in South India. Hum Mol Genet. 2006, 15 (19): 2880-2887. 10.1093/hmg/ddl229.View ArticlePubMedGoogle Scholar
  16. Schauf V, Ryan S, Scollard D, Jonasson O, Brown A, Nelson K, Smith T, Vithayasai V: Leprosy associated with HLA-DR2 and DQw1 in the population of northern Thailand. Tissue Antigens. 1985, 26: 243-247.View ArticlePubMedGoogle Scholar
  17. Soebono H, Giphart MJ, Schreuder GM, Klatser PR, de Vries RR: Associations between HLA-DRB1 alleles and leprosy in an Indonesian population. Int J Lepr Other Mycobact Dis. 1997, 65 (2): 190-6.PubMedGoogle Scholar
  18. Motta PM, Cech N, Fontan C, Giménez MF, Lodeiro N, Marinic K, Molinari ML, Sotelo MG, Habegger de Sorrentino A: Role of HLA-DR and HLA-DQ alleles in multibacillary leprosy and paucibacillary leprosy in the province of Chaco (Argentina). Enferm Infec Microbiol Clin. 2007, 25 (10): 627-631. 10.1157/13112938.View ArticleGoogle Scholar
  19. van Eden W, de Vries RR, D'Amaro J, Schreuder I, Leiker DL, Van Rood JJ: HLA-DR-associated genetic control of the type of leprosy in a population from Surinam. Hum Immunol. 1982, 4: 343-350. 10.1016/0198-8859(82)90007-6.View ArticlePubMedGoogle Scholar
  20. Gorodezky C, Flores J, Arevalo N, Castro LE, Silva A, Rodriguez O: Tuberculoid leprosy in Mexicans is associated with HLA-DR3. Lepr Rev. 1987, 58: 401-406.PubMedGoogle Scholar
  21. Wang LM, Kimura A, Satoh M, Mineshita S: HLA linked with leprosy in southern China: HLA-linked resistance alleles to leprosy. Int J Lepr Other Mycobact Dis. 1999, 67: 403-408.PubMedGoogle Scholar
  22. Itoh Y, Mizuki N, Shimada T, Azuma F, Itakura M, Kashiwase K, Kikkawa E, Kullski JK, Satake M, Inoko H: High-throughput DNA typing of HLA-A, -B, -C, and -DRB1 loci by a PCR-SSOP-Luminex method in the Japanese population. Immunogenetics. 2005, 57 (10): 717-729. 10.1007/s00251-005-0048-3.View ArticlePubMedGoogle Scholar
  23. Kaplan G, Cohn ZA: Regulation of cell-mediated immunity in lepromatous leprosy. Lepr Rev. 1986, 57 (Suppl 2): 199-202.PubMedGoogle Scholar
  24. Peters ES, Eshiet EL: Male-female (sex) differences in leprosy patients in South Eastern Nigeria: female present late for diagnosis and treatment and have higher rates of deformity. Lepr Rev. 2002, 73: 262-267.PubMedGoogle Scholar
  25. Ravikumar M, Dheenadhayalan V, Rajaram K, Lakshmi SS, Kumaran PP, Paramasivan CN, Balakrishnan K, Pitchappan RM: Associations of HLA-DRB1, DQB1 and DPB1 alleles with pulmonary tuberculosis in south India. Tubercle Lung Dis. 1999, 79: 309-317. 10.1054/tuld.1999.0213.View ArticleGoogle Scholar
  26. Thole JE, Janson AA, Cornelisse Y, Schreuder GM, Wieles B, Naafs B, de Vries RR, Ottenhoff TH: HLA-class II-associated control of antigen recognition by T cells in leprosy: a prominent role for the 30/31-kDa antigens. J Immunol. 1999, 162: 6912-6918.PubMedGoogle Scholar
  27. Alcaïs A, Alter A, Antoni G, Orlova M, Nguyen VT, Singh M, Vanderborght PR, Katoch K, Mira MT, Vu HT, Ngyuen TH, Nguyen NB, Moraes M, Mehra N, Schurr E, Abel L: Stepwise replication identifies a low-producing lymphotoxin-alpha allele as a major risk factor for early onset leprosy. Nat Genet. 2007, 39 (4): 517-522. 10.1038/ng2000.View ArticlePubMedGoogle Scholar
  28. Ottenhoff TH, de Vries RR: HLA class II immune response and suppression genes in leprosy. Int J Lepr Other Mycobact Dis. 1987, 55 (3): 521-34.PubMedGoogle Scholar
  29. Mehra NK, Rajalingam R, Mitra DK, Taneja V, Giphart MJ: Variants of HLA-DR2/DR51 group haplotypes and susceptibility to tuberculoid leprosy and pulmonary tuberculosis in Asian Indians. Int J Lepr Other Mycobact Dis. 1995, 63 (2): 241-248.PubMedGoogle Scholar
  30. van Eden W, de Vries RR, Mehra NK, Vaidya MC, D'Amaro J, van Rood JJ: HLA segregation of tuberculoid leprosy: confirmation of the DR2 marker. J Infect Dis. 1980, 141 (6): 693-701.View ArticlePubMedGoogle Scholar
  31. Todd JR, West BC, McDonald JC: Human leukocyte antigen and leprosy: study in northern Louisiana and review. Rev Infect Dis. 1990, 12 (1): 63-74.View ArticlePubMedGoogle Scholar
  32. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/10/133/prepub

Copyright

© Zhang et al; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement